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Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S224(Figure 1). In summary, in children receiving BMT from both
sibling and alternative donors, a FluBu4 backbone  ATG or
low dose radiation was an exceptionally well-tolerated
conditioning regimen that resulted in prompt and reliable
engraftment. Relapse rates and overall survival were similar
to those seen with other myeloablative regimens.301
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With the absence of speciﬁc clinical practice guidelines for
the management of febrile pediatric HSCT patients, many
institutions apply oncology febrile neutropenia guidelines to
pediatric HSCT patients. Recent guidelines regarding the
management of febrile neutropenia in pediatric oncology
patients have questioned the role of sinus CT in their eval-
uation. We sought to determine the predictive factors for
positive ﬁndings on sinus CT and their impact on manage-
ment of febrile pediatric allo-HSCT patients in the ﬁrst year
after transplant. We conducted a retrospective chart review
from 7/1/2007 through 6/30/13. There were 41 febrile epi-
sodes from 37 patients that included sinus CT in the evalu-
ation.19 of the 41 episodes (46%) had positive ﬁndings on the
sinus CT. There was no statistically signiﬁcant difference
between the positive sinus CT and the negative sinus CT
groups with regards to diagnosis, disease status, preparative
regimen, HLA matching/graft source, GVHD, GVHD treat-
ment, presence of NG or ETT, positive blood or urine culture,
or positive ﬁndings on the pre-HSCT sinus CT. The median
time from onset of fever to the sinus CT in the positive sinus
CT group and the negative sinus CT group was not signiﬁ-
cantly different using the log-rank test (256 hrs and 170 hrs,
p¼0.14). Median ANC and APC at onset of fever were signif-
icantly higher in the positive sinus CT group compared to the
negative sinus CT group using the Wilcoxon rank sum test
(2.470109/L and 3.050 109/L versus 0.775109/L and 1.060 109/
L , p¼0.03 and 0.04). 16% of episodes with a positive sinus CT
had no other source of infection identiﬁed, but no episodes
had changes to the pharmacotherapy regimen solely based
on a positive sinus CT. One patient did undergo bilateral
endoscopic maxillary antrostomies and anterior ethmoi-
dostomies, and cultures were positive for Candida glabrata.Sinus CT has a minimal impact on the management of febrile
pediatric allo-HSCT recipients and should be examined in
larger multi-center groups to help develop practice guide-
lines.302
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Alemtuzumab (humanized CD52-monoclonal antibody), a
potent T cell inhibitor, is often included in reduced-intensity
conditioning (RIC) regimens. Modeled on the successes of
such regimens, newer alemtuzumab-containing RIC regi-
mens are being increasingly used for patients with hemo-
globinopathies. We retrospectively reviewed the possible
impact of “late” alemtuzumab (i.e., administered on days -10
through -8) with respect to engraftment and acute/chronic
GvHD in nine pediatric patients (median age 10 y, range 5.1-
18.6yrs)with sickle cell disease who underwent stem cell
transplantation from HLA-matched sibling donors. All pa-
tients received alemtuzumab 10 mg IV daily on days-10
through-8, ﬂudarabine 35 mg/m2/day IV on days-7 to-4, and
melphalan 70 mg/m2 IV on day -3 and day -2. Alemtuzumab
was given relatively close to the day of transplant with intent
to diminish the incidence of graft versus host disease. Eight
out of 9 patients received marrow and 1 patient received
marrow and cord blood. Median nucleated cell dose was 2.3
x 108/kg (Range: 1.46-4.3), with median CD34 cell dose of 1.6
x 106/kg (range: 0.9-5.5). Median time to neutrophil and
platelet engraftment was 15.5 and 36 days, respectively, in
our study. All of the patients received the GvHD prophylactic
regimen comprising of Cyclosporine and Mycophenolate,
both beginning on day -1 of transplant. All patients have
been followed a minimum of 3.5yrs post-transplant.
One patient developed mild acute GvHD of the skin and
another developed limited chronic skin GvHD (taken off
